Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 3/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 0.54 |
| ▸ | RAB9A | P51151 | 10/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445277 | 0.88 | SCN4A (0.79) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2708042 | 0.83 | SCN4A (0.71) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13629452 | 0.81 | SCN4A (0.67) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2710713 | 0.81 | SCN4A (0.67) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4061174 | 0.80 | MAPT (0.77) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2709101 | 0.80 | SCN4A (0.67) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12469024 | 0.79 | SCN4A (0.65) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2710695 | 0.79 | NPC1 (0.76) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10219273 | 0.77 | SCN4A (0.62) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3232592 | 0.76 | SCN4A (0.61) | SCN4ASCN9ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8759382-B2 | Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| EP-2621490-A2 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd. (IL) | 2013-08-07 | — | — | EP | disclosed |
| CN-103209980-A | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PF MEDICAMENT | 2013-07-17 | — | — | CN | disclosed |
| US-20130172364-A1 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-07-04 | — | — | US | disclosed |
| US-20130172364-A1 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012050971-A2 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | SCN4A 42/4885SCN9A 78/4885NPC1 832/4885 |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | SCN4A 42/4885SCN9A 78/4885NPC1 832/4885 |
| US-20130172364-A1 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | PARK7, SNCA, PMP22 | SCN4A 1420/4885SCN9A 2465/4885NPC1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.